A novel coronavirus vaccine trial in the US has now given a dose to its first participant, the National Institute of Allergy and Infectious Diseases announced Monday.
The study aims to enroll a total of 45 healthy adults over a six-week time frame. Each participant will receive two injections about a month apart in varying doses.
The study, which is a Phase I trial, is meant to establish that the vaccine is safe and induces a desired response from participants' immune systems. Proving that the vaccine is effective in preventing COVID-19 infection, however, will require follow-up studies involving many more participants, which will take many more months, experts say.
Please select this link to read the complete article from CNN.